AcousticaBio
Founded 2023 · 1 employees on LinkedIn · 2 known investors
Acoustica.bio develops acoustophoretic technology and microgel suspension formulations that concentrate biologic drugs (such as monoclonal antibodies) to ultra-high concentrations exceeding 500 mg/mL for small-volume subcutaneous injection. It serves drug developers, aiming to convert hospital-based intravenous therapies into patient-friendly at-home injections in the biotech/drug delivery space.
Also known as Acoustica Bio · Acoustica.bio
Founders & leadership
AcousticaBio was founded in 2023 by Daniele Foresti.
Investors · 2
Company profile
researched Aug 2026AcousticaBio is a drug delivery and formulation company that works with drug developers to reformulate new and existing biologic products, particularly monoclonal antibodies (mAbs), into ultra-high-concentration subcutaneous injections. Its stated aim is to convert therapies that are currently given as lengthy hospital- or infusion-center-based intravenous administrations into small-volume injections that can be given outside clinical settings, including at home.
The company frames the core obstacle to subcutaneous delivery as a formulation problem: at the concentrations required for small-volume dosing, monoclonal antibodies tend to become highly viscous and unstable, which complicates manufacturing, processing and injection. According to the company, fewer than half of approved mAbs are available in subcutaneous form, and those that are tend to be lower-dose products or require large injection volumes. AcousticaBio positions its platform as a way to address these viscosity and stability constraints while preserving product integrity.
Business model
The company works with drug developers to formulate their biologic products into ultra-high-concentration subcutaneous presentations using its proprietary platform.
Traction
Selection as an ARPA-H Investor Catalyst Hub spoke network member in October 2024.
Latest developments
In October 2024, the company announced its selection as a spoke of the ARPA-H Investor Catalyst Hub network. It is also recruiting, with open interest in candidates directed to email contact.
▸Full profile — market position, technology, go-to-market
Market position
AcousticaBio addresses the subcutaneous conversion segment of biologics formulation, where high-concentration mAb viscosity and stability limits have kept most approved monoclonal antibodies from having small-volume subcutaneous presentations.
Technology
AcousticaBio's platform combines proprietary acoustophoretic technology with microgel suspension formulations to produce biologic concentrations exceeding 500 mg/mL. Antibodies are encapsulated and stabilized within a polymer matrix and delivered as particle suspensions, which the company says lowers viscosity relative to conventional high-concentration liquid formulations, reduces antibody aggregation, and allows higher payload concentrations with greater stability. The company describes the process as gentle in handling and versatile across a broad range of materials, with minimal product loss. Claimed downstream benefits include injections suitable for self-administration, reduced severity of immune responses, and lower costs for patients, providers and pharmaceutical companies.
Go-to-market
Pharmaceutical and biotech drug developers with biologic and monoclonal antibody products, particularly those currently administered intravenously; end beneficiaries are patients receiving infusion therapies and the clinics and care teams that administer them.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $324.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 1
launches, deals, and filingsAcousticaBio announced it was selected as a spoke in the ARPA-H Investor Catalyst Hub network.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- AcousticaBioacoustica.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AcousticaBio do?
- AcousticaBio uses acoustophoretic processing to formulate biologics as ultra-high-concentration subcutaneous injections.
- Who founded AcousticaBio?
- AcousticaBio was founded by Daniele Foresti in 2023.
- Who are AcousticaBio's investors?
- AcousticaBio's investors include 3CC | Third Culture Capital, Safar Partners.